Philippe F. Backeljauw, MD
- Consultant, Cincinnati Center for Pediatric and Adult Turner Syndrome Care
- Consultant, Center for Growth Disorders
- Professor, UC Department of Pediatrics
- philippe.backeljauw@cchmc.org
- Board Certified
About
Biography
I am a pediatric endocrinologist who specifically treats patients with growth disorders and patients with Turner syndrome. I believe in an honest, open and completely transparent dialogue with the patient and family.
During my fellowship training, which involved both patient care and research, I developed my passion for improving the diagnosis and treatment of growth disorders. My mentorship at the University of North Carolina at Chapel Hill with Dr. Judson Van Wyk and Dr. Louis Underwood, two of the “greats” in this field, convinced me that this was the area I would pursue.
I believe in a rational approach to the work-up and management of children with concerns regarding growth and physical development. I adhere to a cost-conscious approach and guide myself first by a detailed history and exam, rather than jumping to nondiscriminatory testing. I also follow a stepwise approach to solving the medical problem, knowing we may not always find a specific cause for the child’s growth problem. This is something parents should always keep in mind.
I am currently on the board of directors of the Pediatric Endocrine Society and the American Board of Pediatrics Endocrinology Subboard. My past research led to the Food and Drug Administration approval of a growth peptide to treat patients with growth hormone resistance (rhIGF-1), and I’m an international expert in the area of growth hormone resistance.
My current research seeks to find better diagnostic approaches to solving problems related to poor childhood growth. We are also evaluating newer methods for the treatment of growth disorders and how to treat novel growth disorders. In addition, I am involved in several research projects related to the comorbidities of Turner syndrome, for which we are serving the largest clinical cohort in the U.S.
I have published more than 100 peer-reviewed manuscripts, more than 100 abstracts and 17 textbook chapters. I’ve also given more than 90 invited presentations at national and international meetings.
In my free time, I love being in nature. I’m active in hiking, cycling, swimming, kayaking and golf. I also like to read nonfiction books related to philosophy and history.
MD: University of Ghent, Belgium.
Residency: Pediatric and Adolescent Medicine, Cleveland Clinic Foundation Children's Hospital, Cleveland, OH.
Fellowship: Pediatric Endocrinology, University of North Carolina, Chapel Hill, NC.
Certification: Pediatrics, 1992; recertified, 1999, 2007; Pediatric Endocrinology, 1995; recertified, 2003, 2013.
Interests
Consultant for growth disorders and Turner syndrome
Services and Specialties
Endocrinology, Diabetes
Interests
Growth disorders and Turner syndrome
Research Areas
Endocrinology
Additional Languages
French, SpanishPublications
7933 Baseline Demographics and Design of the SkybriGHt Registry Study. A US Multi-center, Prospective, Non-interventional, Long-term, Effectiveness and Safety Study of Children and Adolescents with Growth Hormone Deficiency Treated with Lonapegsomatropin. Journal of the Endocrine Society. 2024; 8:bvae163.1413.
6448 Metabolic Profile and Adipose Tissue Distribution of Young Individuals with Turner Syndrome. Journal of the Endocrine Society. 2024; 8:bvae163.1484.
Clinical practice guidelines for the care of girls and women with Turner syndrome. European Journal of Endocrinology (EJE). 2024; 190:G53-G151.
Pediatric growth hormone deficiency: Understanding the patient and caregiver perspectives. Growth Hormone and IGF Research. 2024; 76:101592.
Safety and Effectiveness of a Biosimilar Recombinant Human Growth Hormone in Children Requiring Growth Hormone Treatment: Analysis of Final Data from PATRO Children, an International, Post-Marketing Surveillance Study. Drug Design, Development and Therapy. 2024; 18:667-684.
Current Recommended Estrogen Dosing for Pubertal Induction in Turner Syndrome Results in Normal Uterine Growth. The Journal of Clinical Endocrinology and Metabolism. 2024; 109:e1040-e1047.
Growth hormone treatment in children with Prader-Willi syndrome: safety and effectiveness data from the PATRO Children study. Therapeutic Advances in Endocrinology and Metabolism. 2024; 15:20420188241264343.
Recombinant Human Insulin-Like Growth Factor-1 Treatment of Severe Growth Failure in Three Siblings with STAT5B Deficiency. Hormone Research in Paediatrics: from developmental endocrinology to clinical research. 2024; 97:195-202.
Challenges in the care of individuals with severe primary insulin-like growth factor-I deficiency (SPIGFD): an international, multi-stakeholder perspective. Orphanet Journal of Rare Diseases. 2023; 18:312.
Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency. Journal of the Endocrine Society. 2023; 7:bvad115.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey